Michael (Yiru) Xu, PhD, MBA
About Michael (Yiru) Xu, PhD, MBA
Michael (Yiru) Xu, PhD, MBA, is an Early Clinical Development professional at Bristol Myers Squibb, with a background in biomedical research and higher education.
Title
Michael (Yiru) Xu, PhD, MBA currently holds a position in Early Clinical Development at Bristol Myers Squibb in Princeton, New Jersey, United States. In this role, he leads early phase clinical development projects focusing on Cardiovascular, Immunology, and Fibrosis.
Work at Bristol Myers Squibb
At Bristol Myers Squibb, Michael (Yiru) Xu is involved in heading early phase clinical development projects, particularly in the specialized areas of Cardiovascular, Immunology, and Fibrosis. His work is pivotal in advancing the biopharmaceutical sector by integrating innovative methods with rigorous analytical and critical thinking approaches.
Academic Career at University of Michigan
Michael (Yiru) Xu served as an Associate Professor at the University of Michigan Medical School from 2008 to 2016. During his tenure in Ann Arbor, Michigan, he significantly contributed to biomedical research and development and mentored the next generation of professionals in the field.
Education and Expertise
Michael (Yiru) Xu has an extensive and diverse educational background. He earned his PhD in Microbiology and Immunology from the Medical College of Wisconsin. Additionally, he holds an MBA with a concentration in Finance, Marketing, and Pharmaceutical Management from Rutgers Business School. He also holds a Bachelor of Science in Biochemistry from Fudan University. His unique blend of expertise spans both the scientific and business facets of medicine, enabling him to bridge these areas effectively.
Research and Development Contributions
Michael (Yiru) Xu has a proven track record in biomedical research and development. His contributions to the field are significant, marked by his innovative mindset and strong analytical skills. His work includes leading clinical development projects and integrating cutting-edge research methodologies to foster growth in the biopharmaceutical industry.